OREANDA-NEWS. January 27, 2016. TransCelerate BioPharma Inc. announced the launch of the Shared Investigator Platform (SIP), a technology that will allow clinical trial sites to streamline investigative site information, and establish a central access point for interaction between the site and multiple clinical trial sponsors.

Cognizant is the overall system integrator and service provider, selected by TransCelerate to design, build and host the SIP.

To ensure the investigator site perspective was included in the design of the system, participating TransCelerate Member Companies collaborated with Investigators through a Site Advocacy Group provided through a partnership with the Society for Clinical Research Sites (SCRS).

The interface for the delivery of content and services to sites was developed by Cognizant. Cognizant incorporated capabilities by CA Technologies, DrugDev, Exostar, LifeRay and SumTotal in bringing the innovative vision of the TransCelerate Member Companies to life.

The SIP will facilitate and simplify interaction between investigators and multiple clinical trial sponsors. With the SIP, sites will experience:

- Increased efficiency and reduced administrative burden in clinical trial planning and conduct

- Streamlined interactions, and consistent data and processes with participating SIP Sponsors

- Reduction of data entry requirements?the ability to enter data once, and have that data re-used across SIP Studies and Sponsors

With SIP, sites can maintain more meaningful collaborations with Sponsors and investigators spend more time on what matters most?their patients.